Cargando…

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

AIM: Chemotherapy-induced toxicity is an independent prognostic indicator in several cancers. We aimed to determine whether toxicity was related to survival and histological response in high-grade localised extremity osteosarcoma. We undertook a retrospective analysis of patients treated within thre...

Descripción completa

Detalles Bibliográficos
Autores principales: McTiernan, Anne, Jinks, Rachel C., Sydes, Matthew R., Uscinska, Barbara, Hook, Jane M., van Glabbeke, Martine, Bramwell, Vivien, Lewis, Ian J., Taminiau, Antonie H.M., Nooij, Marianne A., Hogendoorn, Pancras C.W., Gelderblom, Hans, Whelan, Jeremy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657154/
https://www.ncbi.nlm.nih.gov/pubmed/22036088
http://dx.doi.org/10.1016/j.ejca.2011.09.012
_version_ 1782270101353922560
author McTiernan, Anne
Jinks, Rachel C.
Sydes, Matthew R.
Uscinska, Barbara
Hook, Jane M.
van Glabbeke, Martine
Bramwell, Vivien
Lewis, Ian J.
Taminiau, Antonie H.M.
Nooij, Marianne A.
Hogendoorn, Pancras C.W.
Gelderblom, Hans
Whelan, Jeremy S.
author_facet McTiernan, Anne
Jinks, Rachel C.
Sydes, Matthew R.
Uscinska, Barbara
Hook, Jane M.
van Glabbeke, Martine
Bramwell, Vivien
Lewis, Ian J.
Taminiau, Antonie H.M.
Nooij, Marianne A.
Hogendoorn, Pancras C.W.
Gelderblom, Hans
Whelan, Jeremy S.
author_sort McTiernan, Anne
collection PubMed
description AIM: Chemotherapy-induced toxicity is an independent prognostic indicator in several cancers. We aimed to determine whether toxicity was related to survival and histological response in high-grade localised extremity osteosarcoma. We undertook a retrospective analysis of patients treated within three consecutive randomised controlled trials (RCTs) of the European Osteosarcoma Intergroup. METHODS: Between 1982 and 2002, 533 patients were randomised to six cycles of doxorubicin 75 mg/m(2) and cisplatin 100 mg/m(2). Toxicity data were collected prospectively and graded according to the World Health Organisation (WHO) criteria. Standard univariate and multivariate models were constructed to examine the relationship between reported toxicity, survival, and histological response. RESULTS: Five- and 10-year overall survival was 57% (95% confidence interval (CI) 52–61%) and 53% (49–58%), respectively. Grades 3–4 oral mucositis (hazard ratio (HR) 0.51, 95% CI 0.29–0.91), grades 1–2 nausea/vomiting (HR 0.37, 95% CI 0.16–0.85), grades 1–2 thrombocytopenia (HR 0.49, 95% CI 0.27–0.87), good histological response (HR 0.42, 95% CI 0.27–0.65), and distal tumour site (HR 0.45, 95% CI 0.28–0.71) were associated with improved survival in multivariate analysis. The only factors that were independently associated with histological response were older age (odds ratio (OR) 0.18, 95% CI 0.04–0.72) and chondroblastic tumour (OR 0.28, 95% CI 0.10–0.77), both being associated with a significantly lower chance of achieving a good response. CONCLUSION: Chemotherapy-induced toxicity predicts survival in patients with localised extremity osteosarcoma. Investigation of the pharmacogenomic mechanisms of constitutional chemosensitivity underlying these observations will present opportunities for personalising treatment and could lead to improved outcomes.
format Online
Article
Text
id pubmed-3657154
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Elsevier Science Ltd
record_format MEDLINE/PubMed
spelling pubmed-36571542013-05-18 Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup McTiernan, Anne Jinks, Rachel C. Sydes, Matthew R. Uscinska, Barbara Hook, Jane M. van Glabbeke, Martine Bramwell, Vivien Lewis, Ian J. Taminiau, Antonie H.M. Nooij, Marianne A. Hogendoorn, Pancras C.W. Gelderblom, Hans Whelan, Jeremy S. Eur J Cancer Article AIM: Chemotherapy-induced toxicity is an independent prognostic indicator in several cancers. We aimed to determine whether toxicity was related to survival and histological response in high-grade localised extremity osteosarcoma. We undertook a retrospective analysis of patients treated within three consecutive randomised controlled trials (RCTs) of the European Osteosarcoma Intergroup. METHODS: Between 1982 and 2002, 533 patients were randomised to six cycles of doxorubicin 75 mg/m(2) and cisplatin 100 mg/m(2). Toxicity data were collected prospectively and graded according to the World Health Organisation (WHO) criteria. Standard univariate and multivariate models were constructed to examine the relationship between reported toxicity, survival, and histological response. RESULTS: Five- and 10-year overall survival was 57% (95% confidence interval (CI) 52–61%) and 53% (49–58%), respectively. Grades 3–4 oral mucositis (hazard ratio (HR) 0.51, 95% CI 0.29–0.91), grades 1–2 nausea/vomiting (HR 0.37, 95% CI 0.16–0.85), grades 1–2 thrombocytopenia (HR 0.49, 95% CI 0.27–0.87), good histological response (HR 0.42, 95% CI 0.27–0.65), and distal tumour site (HR 0.45, 95% CI 0.28–0.71) were associated with improved survival in multivariate analysis. The only factors that were independently associated with histological response were older age (odds ratio (OR) 0.18, 95% CI 0.04–0.72) and chondroblastic tumour (OR 0.28, 95% CI 0.10–0.77), both being associated with a significantly lower chance of achieving a good response. CONCLUSION: Chemotherapy-induced toxicity predicts survival in patients with localised extremity osteosarcoma. Investigation of the pharmacogenomic mechanisms of constitutional chemosensitivity underlying these observations will present opportunities for personalising treatment and could lead to improved outcomes. Elsevier Science Ltd 2012-03 /pmc/articles/PMC3657154/ /pubmed/22036088 http://dx.doi.org/10.1016/j.ejca.2011.09.012 Text en © 2012 Elsevier Ltd. https://creativecommons.org/licenses/by/3.0/ Open Access under CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/) license
spellingShingle Article
McTiernan, Anne
Jinks, Rachel C.
Sydes, Matthew R.
Uscinska, Barbara
Hook, Jane M.
van Glabbeke, Martine
Bramwell, Vivien
Lewis, Ian J.
Taminiau, Antonie H.M.
Nooij, Marianne A.
Hogendoorn, Pancras C.W.
Gelderblom, Hans
Whelan, Jeremy S.
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
title Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
title_full Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
title_fullStr Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
title_full_unstemmed Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
title_short Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
title_sort presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the european osteosarcoma intergroup
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657154/
https://www.ncbi.nlm.nih.gov/pubmed/22036088
http://dx.doi.org/10.1016/j.ejca.2011.09.012
work_keys_str_mv AT mctiernananne presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT jinksrachelc presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT sydesmatthewr presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT uscinskabarbara presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT hookjanem presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT vanglabbekemartine presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT bramwellvivien presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT lewisianj presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT taminiauantoniehm presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT nooijmariannea presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT hogendoornpancrascw presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT gelderblomhans presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup
AT whelanjeremys presenceofchemotherapyinducedtoxicitypredictsimprovedsurvivalinpatientswithlocalisedextremityosteosarcomatreatedwithdoxorubicinandcisplatinareportfromtheeuropeanosteosarcomaintergroup